Trial Profile
A Phase 1, Single-Center, Dose-Escalation Study to Determine the Safety and Pharmacokinetics of a Single Oral Dose of PF614 in Healthy Subjects Compared to OxyContin®
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Aug 2018
Price :
$35
*
At a glance
- Drugs Oxycodone (Primary)
- Indications Pain
- Focus Adverse reactions
- Acronyms SAD
- Sponsors Ensysce Biosciences
- 29 Jan 2018 Status changed from recruiting to completed, according to a Ensysce Biosciences.
- 02 Dec 2017 Cohort 7 has been added into the study and 16 subjects were enrolled for the cohort.
- 02 Dec 2017 Planned number of patients changed from 48 to 64.